文献速递淋巴瘤

2p获得导致REL过表达及NF-κB持续激活介导CLL对BTK抑制剂耐药

REL overexpression and sustained NF-κB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.
PubMed 文献 · Leukemia · 2025-12-09

该研究探讨了慢性淋巴细胞白血病(CLL)中2p染色体获得(2p+)介导BTK抑制剂(BTKi)耐药的机制。单细胞RNA测序显示2p+ B细胞中NF-κB通路富集且REL过表达,体外实验证实2p+原代CLL样本REL表达及DNA结合活性增高,对共价及非共价BTKi敏感性降低。CRISPR/Cas9失活REL可恢复BTKi敏感性,临床数据显示2p+患者BTKi治疗后至下次治疗时间更短。

要点

  • 2p+ CLL细胞中REL过表达且NF-κB通路持续激活。
  • 2p+ CLL细胞对共价和非共价BTKi敏感性降低。
  • 检测2p获得有助于指导CLL的BTKi治疗策略。

核心结论

  • REL过表达是2p+驱动的CLL对BTKi耐药的新机制,补充了BTK和PLCG2突变以外的耐药解释。

研究设计与样本

  • 研究对2p+ CLL进行单细胞RNA测序,并在大样本2p+原代CLL样本中开展体外分析。
  • 利用CRISPR/Cas9在2p+ B淋巴样细胞系中失活REL,并分析临床2p+ CLL患者BTKi治疗后的结局。

主要发现

  • 单细胞RNA测序显示2p+ B细胞中NF-κB通路富集且REL过表达。
  • 体外分析证实大样本2p+原代CLL样本中REL表达及DNA结合活性增高。
  • 2p+ CLL细胞对共价和非共价BTKi的敏感性均降低。
  • 伊布替尼处理后,BCR刺激下2pWT CLL细胞REL DNA结合活性下降,而2p+ CLL细胞中持续存在。
  • CRISPR/Cas9失活2p+ B淋巴样细胞系中的REL可下调经典NF-κB信号并恢复BTKi敏感性。

临床怎么用

  • 检测2p获得可能有助于识别BTKi耐药风险较高的CLL患者并指导治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The gain of chromosome 2p (2p+) is a recurrent abnormality in chronic lymphocytic leukemia (CLL), frequently observed in advanced or relapsed disease, associated with poor prognosis and reduced response to Bruton's tyrosine kinase inhibitors (BTKi). To investigate the mechanisms of 2p+-mediated resistance, we performed single-cell RNA sequencing, revealing NF-κB pathway enrichment and REL overexpression in 2p+ B cells. In vitro analyses confirmed increased REL expression and DNA-binding activity in a large cohort of 2p+ primary CLL samples. Functionally, 2p+ CLL cells showed reduced sensitivity to both covalent and non-covalent BTKi. Moreover, upon ibrutinib treatment, REL DNA-binding activity decreased in 2pWT CLL cells but remained sustained in 2p+ CLL cells following BCR stimulation, suggesting that persistent NF-κB activation contributes to resistance. Consistently, CRISPR/Cas9-mediated inactivation of REL in a 2p+ B-lymphoid cell line led to downregulation of canonical NF-κB signaling and restored BTKi sensitivity. Clinically, patients with 2p+ CLL treated with BTKi had a shorter time-to-next-treatment than 2pWT patients. Altogether, our study identifies REL overexpression as a novel 2p+-driven mechanism of BTKi resistance in CLL, complementing the well described BTK and PLCG2 mutations. These findings support the clinical relevance of detecting 2p gain to guide treatment strategies and improve outcomes in CLL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dehgane L, Mallet E, Brasseur C, et al. REL overexpression and sustained NF-κB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia. Leukemia. 2025. PMID: 41366531. doi:10.1038/s41375-025-02818-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。